AstraZeneca adds to Zactima Phase III lung cancer program
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
AstraZeneca continues to pursue broad labeling for its oral targeted therapy Zactima (vandetanib) with a fourth Phase III trial in non-small cell lung cancer. The recently initiated trial, Study 36, will add data on another chemotherapy combination, with Lilly's Alimta (pemetrexed). An ongoing Phase III, Study 32, combines Zactima with Sanofi-Aventis' Taxotere (docetaxel), a combination that was also part of the Phase II program. AZ also tested single-agent Zactima in Phase II; ongoing Phase III Study 57 is evaluating monotherapy with Zactima or Genentech's Tarceva (erlotinib) in a head-to-head targeted therapy comparison in second- and third-line NSCLC. Another Phase III trial is enrolling in third- and fourth-line patients who have failed both chemotherapy and an EGFR inhibitor like Tarceva. The newest Phase III is expected to enroll 508 patients who failed at least one chemotherapy regimen; the first patient entered Study 36 in January 2007. Progression-free survival is the primary endpoint of Study 36...
You may also be interested in...
R&D In Brief
AtheroGenics AGI-1067 dose range restricted in Phase III due to liver concerns: The high-dose 300 mg arm of AtheroGenics' Phase III ANDES trial will be discontinued due to liver toxicity concerns, the company announces Nov. 9. Additional analysis of an earlier Phase III study, ARISE, found rare adverse effects on the liver with a 300 mg dose of the oral anti-inflammatory antioxidant AGI-1067. ANDES was designed to elucidate subgroup effects seen in diabetic patients enrolled in ARISE, a pivotal atherosclerosis trial that failed to meet its primary cardiovascular event endpoint. AtheroGenics and then-partner AstraZeneca had hoped ARISE would support multiple claims for AGI-1067 in subgroups. After the stumble with ARISE, AtheroGenics shifted its focus for AGI-1067 from atherosclerosis to glycemic control in type 2 diabetes. ANDES started enrolling diabetes patients in August as a dose-ranging trial to confirm the ARISE diabetes findings. The trial will continue with the two lower-dose arms (75 and 150 mg); an interim analysis is planned for the second quarter of 2008...
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.